Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL948434 | 0.94 | ALDH1A1 (0.32) | SMN1; SMN2CYP2A13ALDH1A1HPGD | |
| SCHEMBL1582708 | 0.92 | MAPT (0.33) | SMN1; SMN2CYP2A13ALDH1A1HPGD | |
| SCHEMBL2778573 | 0.84 | — | — | |
| SCHEMBL2241191 | 0.81 | — | — | |
| SCHEMBL236881 | 0.81 | CYP2D6 (0.30) | — | |
| SCHEMBL731008 | 0.79 | — | — | |
| SCHEMBL969556 | 0.77 | — | — | |
| SCHEMBL157427 | 0.75 | CYP2D6 (0.33) | — | |
| SCHEMBL1428236 | 0.75 | — | — | |
| SCHEMBL12466533 | 0.74 | KDM4E (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170051149-A1 | AZOARYLS AS REVERSIBLY MODULATABLE TUBULIN INHIBITORS | ECOLE NORMALE SUPERIEURE DE LYON (FR) | 2017-02-23 | — | — | US | claimed |
| EP-1809601-B1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MANFREDI JOHN (US) | 2014-09-10 | — | — | EP | claimed |
| US-20120225845-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | claimed |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | claimed |
| US-20100184975-A1 | COMPOUNDS FOR ALZHEIMBER'S DISEASE | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | US | claimed |
| US-7678823-B2 | N-phenylindoles; oral dosage forms; side effect reduction | Myriad Pharmaceticals, Inc. (US) | 2010-03-16 | — | — | US | claimed |
| US-7605156-B2 | Methods for the use of inhibitors of cytosolic phospholipase A2 | WYETH (US) | 2009-10-20 | — | — | US | claimed |
| US-7541359-B2 | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-02 | — | — | US | claimed |
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-16 | — | — | US | claimed |
| EP-2010187-A2 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2009-01-07 | — | — | EP | claimed |
| US-7087631-B2 | Aryltetrazole compounds, and compositions thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-08-08 | — | — | US | claimed |
| US-7078423-B2 | 5-Aryltetrazole compounds, compositions thereof, and uses therefor | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-07-18 | — | — | US | claimed |
| WO-2006041874-A2 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYRIAD GENETICS, INC. (US) | 2006-04-20 | — | — | WO | claimed |
| EP-1542980-A1 | 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR | Inotek Pharmaceuticals Corporation (US) | 2005-06-22 | — | — | EP | claimed |
| US-20040116423-A1 | 5-Aryltetrazole compounds, compositions thereof, and uses therefor | INOTEK PHARMACEUTICALS CORPORATION | 2004-06-17 | — | — | US | claimed |
| WO-2004009563-A1 | 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR | INOTEK PHARMACEUTICALS CORPORATION (US) | 2004-01-29 | — | — | WO | claimed |
| US-20040019208-A1 | 5-Aryltetrazole Compounds, compositions thereof, and uses therefor | INOTEK PHARMACEUTICALS CORPORATION | 2004-01-29 | — | — | US | claimed |
| US-6063181-A | 1,7-disubstituted perylene-3,4,9, 10-tetracarboxylic acids, their dianhydrides and diimides of said acids | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-16 | — | — | US | claimed |
| EP-0213718-B1 | 1-DIMETHYLCARBAMOYL-3-SUBSTITUTED-5-SUBSTITUTED-1H-1,2,4-TRIAZOLES | ROHM AND HAAS COMPANY (US) | 1991-06-12 | — | — | EP | claimed |
| EP-0213718-A2 | 1-Dimethylcarbamoyl-3-substituted-5-substituted-1H-1,2,4-triazoles | ROHM AND HAAS COMPANY (US) | 1987-03-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | CLN6, NLN, CLTC | SMN1; SMN2 76/4885CYP2A13 2910/4885ALDH1A1 1938/4885 |
| US-20120225845-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | CLN6, NLN, CLTC | SMN1; SMN2 76/4885CYP2A13 2910/4885ALDH1A1 1938/4885 |
| US-20100184975-A1 | COMPOUNDS FOR ALZHEIMBER'S DISEASE | PSEN2, PSEN1, CLN6 | SMN1; SMN2 894/4885CYP2A13 1871/4885ALDH1A1 1225/4885 |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | PSEN2, CHAT, PSEN1 | SMN1; SMN2 1033/4885CYP2A13 2247/4885ALDH1A1 1321/4885 |
| US-20040019208-A1 | 5-Aryltetrazole Compounds, compositions thereof, and uses therefor | CASP5, NLRP3, LITAF | SMN1; SMN2 3942/4885CYP2A13 421/4885ALDH1A1 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.